clinical trial · NCT05323656
A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)
Calliditas Therapeutics Suisse SA·phase2·completed·n = 55
Squamous Cell Carcinoma of Head and NeckSetanaxibPembrolizumabPlacebo
brief summary
The primary objective of this study is to compare the change in tumour size per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in recurrent or metastatic SCCHN patients treated with setanaxib and pembrolizumab versus patients treated with placebo and pembrolizumab.
started
Apr 6, 2022
primary completion
Feb 18, 2024
completion
Aug 21, 2025
last updated
Sep 2, 2025
official title
A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Setanaxib, When Administered With Pembrolizumab, in Patients With Recurrent or Metastatic SCCHN
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol